Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
NCT00709761
Completed
This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Sixty subjects were to be enrolled in the study. Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib (1000 mg once daily). Subjects were to receive treatment until disease prog... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/01/2019
Locations: Novartis Investigative Site, La Verne, California +12 locations
Conditions: Neoplasms, Breast
Register for Updates
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
NCT01881230
Completed
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/19/2019
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +139 locations
Conditions: Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer, Metastatic Breast Cancer
Register for Updates
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02050009
Withdrawn
This phase I trial studies the side effects and best way to give metformin hydrochloride, carboplatin, and paclitaxel in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as metformin hydrochloride, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2019
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer
Register for Updates
GSK1120212 Rollover Study
NCT01376310
Terminated
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2019
Locations: Novartis Investigative Site, Goodyear, Arizona +18 locations
Conditions: Cancer
Register for Updates
Neoadjuvant Treatment of Breast Cancer
NCT00254592
Completed
Study Aims 1. To measure the clinic response rates in patients with breast cancer more than 2 cm and/or lymph node positive breast cancer treated with 2-4 cycles of biweekly doxorubicin, cyclophosphamide with Granulocyte-macrophage colony-stimulating factor (GM-CSF) (days 4-13) followed by weekly carboplatin/nab-paclitaxel given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. (Her-2 positive patients, in addition, will receive Trastuzumab weekly (12-16 doses) and Her-2 negat... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/13/2019
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Breast Cancer
Register for Updates
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
NCT02732938
Terminated
The purpose of this Phase 1b/2 study is to evaluate the safety and tolerability of PF-04136309 in combination with nab-paclitaxel and gemcitabine, characterize the dose-limiting toxicities (DLTs) and overall safety profile of escalated doses of PF-04136309 and the associated schedule, determine the maximum tolerated dose (MTD), and to assess the enhancement of efficacy of PF-04136309 in combination with nab-paclitaxel and gemcitabine versus nab-paclitaxel + gemcitabine + placebo in terms of Prog... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2019
Locations: Massachusetts General Hospital, Boston, Massachusetts +17 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
NCT00403130
Completed
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/30/2019
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
CHFR Methylation Status Esophageal Cancer Study
NCT01372202
Terminated
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/23/2019
Locations: Ronan Kelly, M.D., Baltimore, Maryland
Conditions: Esophageal Cancer
Register for Updates
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
NCT02364999
Completed
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2019
Locations: Southern Cancer Center, PC, Daphne, Alabama +262 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00495170
Completed
The goal of this clinical research study is to learn if proton radiotherapy given with standard chemotherapy (such as paclitaxel and carboplatin) can help to control locally advanced NSCLC. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
NCT01632306
Terminated
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2019
Locations: Mayo Clinic of Jacksonville, Jacksonville, Florida +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Preoperative Herceptin and Navelbine for Breast Cancer
NCT00148681
Completed
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2019
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Register for Updates